Selected article for: "cancer patient and novel coronavirus"
Author: Buti, Sebastiano; Perrone, Fabiana; Zielli, Teresa; Mazzaschi, Giulia; Casartelli, Chiara; Leonetti, Alessandro; Milanese, Gianluca; Silva, Mario; Eufrasia Ledda, Roberta; Musolino, Antonino; Pucci, Francesca; Bersanelli, Melissa; Tiseo, Marcello
Title: Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
  • Cord-id: u91anva1
  • Document date: 2021_9_8
    • ID: u91anva1
    Snippet: BACKGROUND: Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group such as cancer patients. The aim of the present study was to evaluate the clinical impact of COVID-19 infection on outcome and oncologic treatment of cancer patients. PATIENT AND METHODS: We retrospectively enrolled cancer patients with laboratory and/o
    Document: BACKGROUND: Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group such as cancer patients. The aim of the present study was to evaluate the clinical impact of COVID-19 infection on outcome and oncologic treatment of cancer patients. PATIENT AND METHODS: We retrospectively enrolled cancer patients with laboratory and/or radiologic confirmed SARS-CoV-2 infection, admitted to our center from February to April 2020. Descriptive statistics were used to summarize the clinical data and univariate analyses were performed to investigate the impact of anticancer treatment modifications due to COVID-19 outbreak on the short-term overall survival (OS). RESULTS: Among 61 patients enrolled, 49 (80%) were undergoing anticancer treatment and 41 (67%) had metastatic disease. Most patients were men; median age was 68 years. Median OS was 46.6 days (40% of deaths occurred within 20 days from COVID-19 diagnosis). Among 59 patients with available data on therapeutic course, 46 experienced consequences on their anticancer treatment schedule. Interruption or a starting failure of the oncologic therapy correlated with significant shorter OS. Anticancer treatment delays did not negatively affect the OS. Lymphocytopenia development after COVID was significantly associated with worst outcome. CONCLUSIONS: COVID-19 diagnosis in cancer patients may affect their short-term OS, especially in case of interruption/starting failure of cancer therapy. Maintaining/delaying cancer therapy seems not to influence the outcome in selected patients with recent COVID-19 diagnosis.

    Search related documents:
    Co phrase search for related documents
    • active anticancer treatment and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4
    • active anticancer treatment and adjuvant neoadjuvant: 1
    • active treatment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active treatment and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active treatment and adjuvant neoadjuvant: 1
    • active treatment and local protocol: 1, 2
    • acute respiratory syndrome and adjuvant neoadjuvant: 1
    • acute respiratory syndrome and administration date: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and local ethical committee: 1
    • acute sars respiratory syndrome coronavirus and administration date: 1, 2, 3, 4, 5